Drug Profile
Research programme: MAP kinase kinase 2 inhibitors - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Alkenes; Amines; Cyclobutanes; Ketones; Quinazolines
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 02 Sep 2011 Preclinical development is ongoing in USA
- 15 Oct 2009 Wyeth has been acquired by Pfizer